A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
MATERIALS SOURCING Low cost, high-quality raw materials and packaging components are essential to all of our business units. Some generic raw materials and packaging components are available from multiple suppliers. However, supplies of certain raw materials and packaging components, due to their technical specifications and product delivery systems, are more limited as they may be available from one, or only a few suppliers, and may require extensive compatibility testing before we can use them. Historically, we have been able to react effectively, yet not always immediately, to situations that require alternate sourcing. Should such alternate sourcing be necessary, FDA requirements placed on products approved through the Abbreviated New Drug Application ("ANDA") or New Drug Application ("NDA") process could substantially lengthen the approval of an alternate source and adversely affect financial results.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 4.3B | 4.3B | 4.4B | 4.7B | 4.5B | 4.1B |
| Net Income | -1.4B | -1.4B | -172M | -13M | -141M | -69M |
| EPS | $-10.29 | $-10.29 | $-1.25 | $-0.09 | $-1.04 | $-0.52 |
| Free Cash Flow | 145M | 145M | 245M | 304M | 211M | 4.2M |
| ROIC | -14.3% | -19.7% | 1.4% | 1.8% | 1.0% | 3.2% |
| Gross Margin | 35.1% | 35.1% | 35.3% | 36.1% | 32.7% | 34.2% |
| Debt/Equity | 1.30 | 1.30 | 0.88 | 0.89 | 0.89 | 0.71 |
| Dividends/Share | $1.15 | $1.16 | $1.10 | $1.09 | $1.04 | $0.96 |
| Operating Income | -1.1B | -1.1B | 113M | 152M | 79M | 410M |
| Operating Margin | -26.4% | -26.4% | 2.6% | 3.3% | 1.8% | 9.9% |
| ROE | -48.6% | -39.3% | -3.8% | -0.3% | -2.8% | -1.3% |
| Shares Outstanding | 139M | 139M | 137M | 141M | 135M | 133M |
PERRIGO Co plc passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 10.9x vs a median of 13.6x. The company's 5-year average gross margin is 34.7%. Total shareholder yield (dividends) is 10.0%. At current prices, the estimated annualized return to fair value is -10.0%.
PERRIGO Co plc (PRGO) has a 5-year average return on invested capital (ROIC) of -2.5%. This is below average and may indicate limited pricing power.
PERRIGO Co plc (PRGO) has a market capitalization of $1.6B. It is classified as a small-cap stock.
Yes, PERRIGO Co plc (PRGO) pays a dividend with a trailing twelve-month yield of 10.03%.
PERRIGO Co plc (PRGO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PERRIGO Co plc (PRGO) reported annual revenue of $4.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
PERRIGO Co plc (PRGO) has a net profit margin of -33.5%. The company is currently unprofitable.
PERRIGO Co plc (PRGO) generated $145 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
PERRIGO Co plc (PRGO) has a debt-to-equity ratio of 1.30. This indicates moderate leverage.
PERRIGO Co plc (PRGO) reported earnings per share (EPS) of $-10.29 in its most recent fiscal year.
PERRIGO Co plc (PRGO) has a return on equity (ROE) of -39.3%. A negative ROE may indicate losses or negative equity.
PERRIGO Co plc (PRGO) has a 5-year average gross margin of 34.7%. This indicates decent pricing power.
The Ledger Terminal provides 14 years of financial data for PERRIGO Co plc (PRGO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PERRIGO Co plc (PRGO) has a book value per share of $21.19, based on its most recent annual SEC filing.
No recent press releases.